{"url_path":"/sec/kapa/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","accession_number":"0001493152-26-022796","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":860,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0001962011\n\n0001962011\n\n2026-01-01\n2026-03-31\n\n0001962011\n\n2026-05-11\n\n0001962011\n\n2026-03-31\n\n0001962011\n\n2025-12-31\n\n0001962011\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001962011\n\n2024-12-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001962011\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001962011\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001962011\n\n2025-03-31\n\n0001962011\n\nKAPA:EnviroThreapeuticsIncMember\n\n2021-12-31\n\n0001962011\n\nKAPA:EquityLineOfCreditMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantsToPurchaseCommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:WarrantsToPurchaseCommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nKAPA:PrevailInfoworksIncMember\n\n2026-03-31\n\n0001962011\n\nKAPA:PrevailInfoworksIncMember\n\n2025-12-31\n\n0001962011\n\nKAPA:CrossCurrentCapitalLLCMember\n\n2026-03-31\n\n0001962011\n\nKAPA:CrossCurrentCapitalLLCMember\n\n2025-12-31\n\n0001962011\n\nKAPA:MasterServiceAndTechnologyAgreementMember\n\n2024-08-01\n2024-08-01\n\n0001962011\n\n2024-10-01\n2024-10-31\n\n0001962011\n\nKAPA:MasterServiceAndTechnologyAgreementMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ConsultingAgreementMember\n\n2024-10-01\n2024-10-01\n\n0001962011\n\nKAPA:ConsultingAgreementMember\n\n2024-12-31\n\n0001962011\n\nKAPA:ConsultingAgreementMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ConsultingAgreementMember\n\n2025-12-31\n\n0001962011\n\nKAPA:HelenaGlobalInvestmentOpportunitiesILTDMember\n\n2024-11-12\n2024-11-12\n\n0001962011\n\n2024-11-12\n2024-11-12\n\n0001962011\n\nKAPA:HelenaGlobalInvestmentOpportunitiesILTDMember\n\n2025-12-31\n\n0001962011\n\nKAPA:HelenaGlobalInvestmentOpportunitiesILTDMember\n\n2026-03-31\n\n0001962011\n\n2026-01-01\n2026-01-31\n\n0001962011\n\nKAPA:ATMAgreementMember\n\n2026-01-01\n2026-01-31\n\n0001962011\n\nKAPA:ATMAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ATMAgreementMember\n\n2026-03-31\n\n0001962011\n\nKAPA:SecurityPurchaseAgreementMember\nKAPA:PreFundedWarrantMember\n\n2025-01-14\n2025-01-14\n\n0001962011\n\nKAPA:SecurityPurchaseAgreementMember\nKAPA:PreFundedWarrantMember\n\n2025-01-14\n\n0001962011\n\nKAPA:SecurityPurchaseAgreementMember\nus-gaap:WarrantMember\n\n2025-01-14\n\n0001962011\n\nKAPA:SecurityPurchaseAgreementMember\n\n2025-01-16\n2025-01-16\n\n0001962011\n\nKAPA:SecurityPurchaseAgreementMember\n\n2025-01-16\n\n0001962011\n\nKAPA:PrefundedWarrantsMember\n\n2025-01-14\n\n0001962011\n\nKAPA:CommonWarrantsMember\n\n2025-01-14\n\n0001962011\n\nKAPA:PrefundedWarrantsMember\n\n2025-01-01\n2025-12-31\n\n0001962011\n\nKAPA:TwentyTwentyThreeEquityIncentivePlanMember\n\n2023-07-31\n\n0001962011\n\nKAPA:TwentyTwentyThreeEquityIncentivePlanMember\n\n2026-03-31\n\n0001962011\n\nKAPA:TwentyTwentyThreeEquityIncentivePlanMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:WarrantMember\nsrt:MinimumMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:WarrantMember\nsrt:MaximumMember\n\n2025-12-31\n\n0001962011\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:WarrantMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001962011\n\nus-gaap:WarrantMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ExercisePriceRangeOneMember\nKAPA:WarrantOneMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ExercisePriceRangeOneMember\nKAPA:WarrantOneMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantOneMember\nKAPA:ExercisePriceRangeOneMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantOneMember\nKAPA:ExercisePriceRangeOneMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExercisePriceRangeTwoMember\nKAPA:WarrantTwoMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ExercisePriceRangeTwoMember\nKAPA:WarrantTwoMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantTwoMember\nKAPA:ExercisePriceRangeTwoMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantTwoMember\nKAPA:ExercisePriceRangeTwoMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExercisePriceRangeThreeMember\nKAPA:WarrantThreeMember\n\n2026-03-31\n\n0001962011\n\nKAPA:WarrantThreeMember\nKAPA:ExercisePriceRangeThreeMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:PhaseOneClinicalTrialMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemOneAndTwoMember\nKAPA:PhaseTwoMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemThreeMember\nKAPA:PhaseTwoClinicalTrialMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:NonUsMember\nKAPA:FoodAndDrugAdministrationMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemOneTwoAndThreeMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemOneTwoAndThreeMember\n\n2025-01-01\n2025-12-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nKAPA:ItemFourMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nKAPA:ItemFourMember\n\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nsrt:MinimumMember\nKAPA:ItemFourMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ExclusiveLicenseAgreementMember\nsrt:MaximumMember\nKAPA:ItemFourMember\n\n2026-01-01\n2026-06-30\n\n0001962011\n\nKAPA:PhaseOneClinicalTrialMember\nKAPA:ItemFourMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:PhaseTwoClinicalTrialMember\nKAPA:ItemFourMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemFourMember\nKAPA:FoodAndDrugAdministrationMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemFourMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:PhaseThreeClinicalTrialMember\nKAPA:EnviroCedarsLicenseAgreementsMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:ItemOneAndTwoMember\nKAPA:PhaseThreeMember\nKAPA:EnviroCedarsLicenseAgreementsMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nKAPA:LonzaAmendmentMember\n\n2025-11-12\n2025-11-12\n\n0001962011\n\nKAPA:LonzaAmendmentMember\n\n2026-03-27\n2026-03-27\n\n0001962011\n\nKAPA:LonzaAmendmentMember\n\n2026-03-31\n2026-03-31\n\n0001962011\n\n2026-03-02\n\n0001962011\n\n2026-03-02\n2026-03-02\n\n0001962011\n\nus-gaap:OperatingSegmentsMember\n\n2026-01-01\n2026-03-31\n\n0001962011\n\nus-gaap:OperatingSegmentsMember\n\n2025-01-01\n2025-03-31\n\n0001962011\n\nKAPA:LonzaAmendmentMember\nus-gaap:SubsequentEventMember\n\n2026-04-01\n2026-04-01\n\n0001962011\n\nus-gaap:SubsequentEventMember\nKAPA:PharmaceuticalDevelopmentServicesAgreementMember\n\n2026-05-11\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nKAPA:Integer\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**☒ QUARTERLY REPORT PURSUANT\nTO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended\nMarch 31, 2026**\n\n \n\n**or**\n\n \n\n**☐ TRANSITION REPORT\nPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period\nfrom ___________ to ___________**\n\n \n\nCommission File Number: 001-42275\n\n \n\n**KAIROS PHARMA, LTD.**\n\n(Exact name of registrant as\nspecified in its charter)\n\n \n\n**Delaware**\n \n**46-2993314**\n\n(State or other jurisdiction\nof\n\nincorporation or organization)\n\n \n\n(I.R.S Employer\n\nIdentification No.)\n\n \n\n**2355 Westwood Blvd., #139\nLos Angeles CA 90064**\n\n(Address of principal executive\noffices) (Zip Code)\n\n \n\n**(310) 948-2356**\n\n(Registrant’s telephone\nnumber, including area code)\n\n \n\nN/A\n\n(Former name, former address\nand former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.001 per share \n \nKAPA\n \nNYSE American\n\n \n\nIndicate by check mark whether the registrant (1)\nhas filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has\nsubmitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of\nthis chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒\nNo ☐\n\n \n\nIndicate by check mark whether the registrant is a\nlarge accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See\nthe definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and\n“emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐\nAccelerated filer ☐\n\nNon-accelerated filer ☒\nSmaller reporting company ☒\n\n \nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check mark\nif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a\nshell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒\n\n \n\nThe number of shares issued and outstanding of the\nregistrant’s common stock on May 11, 2026 was 21,411,198.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**KAIROS PHARMA, LTD.**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n**PART I - FINANCIAL INFORMATION**"}